Dynavax Aims for 60% U.S. Hepatitis B Market Share by 2030 Amid New COVID-19 Vaccine Deal and Expanded Share Repurchase

Dynavax Technologies aims to capture 60% of the US hepatitis B market by 2030, following a new COVID-19 vaccine deal and expanded share repurchase program. CEO Ryan Spencer highlighted top-line growth and market share expansion for HEPLISAV-B, as well as progress in multiple clinical programs and a strategic license with Vaxart for a Phase IIb oral vaccine.